ADC Therapeutics SA (ADCT) Misses Q3 EPS by 1c; Reports $530.2M of Cash and Cash Equivalents

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.93), $0.01 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $7.39 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
• OLB Group narrows net loss 50% as revenue falls in Q2 2026
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c